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and mortality after percutaneous coronary intervention (PCI). It is unclear, however, whether these observed beneﬁts are
inﬂuenced by baseline bleeding risk.
OBJECTIVES This study investigated the relationship between baseline bleeding risk, TRA utilization, and
procedure-related outcomes in patients undergoing PCI enrolled in the British Cardiovascular Intervention Society
database.
METHODS Baseline bleeding risk was calculated by using modiﬁed Mehran bleeding risk scores in 348,689 PCI
procedures performed between 2006 and 2011. Four categories for bleeding risk were deﬁned for the modiﬁed Mehran
risk score (MMRS): low (<10), moderate (10 to 14), high (15 to 19), and very high ($20). The impact of baseline bleeding
risk on 30-day mortality and its relationship with access site were studied.
RESULTS TRA was independently associated with a 35% reduction in 30-day mortality risk (odds ratio [OR]: 0.65
[95% conﬁdence interval (CI): 0.59 to 0.72]; p < 0.0001), with the magnitude of mortality reduction related to baseline
bleeding risk (MMRS <10, OR: 0.73 [95% CI: 0.62 to 0.86]; MMRS $20, OR: 0.53 [95% CI: 0.47 to 0.61]). In patients
with an MMRS <10, TRA was used in 71,771 (43.2%) of 166,083 PCI procedures; TRA was used in 8,655 (40.1%) of 21,559
PCI procedures in patients with an MMRS $20, illustrating that TRA was used less in those at highest risk from bleeding
complications (p < 0.0001).
CONCLUSIONS TRA was independently associated with reduced 30-day mortality, and the magnitude of this effect
was related to baseline bleeding risk; those at highest risk of bleeding complications gained the greatest beneﬁt from
adoption of TRA during PCI. (J Am Coll Cardiol 2014;64:1554–64) © 2014 by the American College of Cardiology
Foundation.m the *Manchester Heart Centre, Manchester Royal Inﬁrmary, Manchester, United Kingdom; yCardiovascular Research Group,
titute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom; zFarr Institute, University of
nchester, Manchester, United Kingdom; xInstitute of Population Health, University of Manchester, Manchester, United
gdom; kUniversity Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom; {The Heart Hospital, University College
ndon Hospitals, London, United Kingdom; #Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust,
ighton, United Kingdom; **The James Cook University Hospital, Middlesbrough, United Kingdom; and the yyQueen Elizabeth
spital, Birmingham, United Kingdom. Dr. de Belder has reported receiving a travel grant fromMedtronic. All other authors have
orted that they have no relationships relevant to the contents of this paper to disclose. Drs. Mamas and Anderson contributed
ually to this work.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
u can also listen to this issue’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
nuscript received March 26, 2014; revised manuscript received May 6, 2014, accepted May 13, 2014.
AB BR E V I A T I O N S
AND ACRONYM S
BCIS = British Cardiovascular
Intervention Society
CABG = coronary artery bypass
graft
CI = conﬁdence interval
MI = myocardial infarction
NHS = National Health Service
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1555A dvances in antithrombotic therapy haveimproved outcomes for patients undergoingpercutaneous coronary intervention (PCI) by
reducing ischemic events and mortality but with a
corresponding increase in procedure-related bleed-
ing complications. These peri-procedural bleeding
complications are associated with adverse clinical out-
comes, including myocardial infarction (MI), stroke,
and death (1–3).SEE PAGE 1565
NSTEMI = non–ST-segment
elevation myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
STEMI = ST-elevation
myocardial infarction
TFA = transfemoral access
TIMI = Thrombolysis In
Myocardial Infarction
= transradial accessA signiﬁcant proportion of such major bleeding
complications are related to the access site. In a post-
hoc analysis of the REPLACE-2 (Randomized Evalua-
tion in PCI Linking Angiomax to Reduced Clinical
Events), ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy), and HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trials, 38.6% of
major bleeds were access site related (4), and in
the RIVAL (Radial vs. Femoral Access for Coronary
Intervention) study, 30% of non–coronary artery
bypass graft (CABG)-related major bleeds were access
site related (5). A proportion of these access site
bleeds correlate to the patients’ syndrome at pre-
sentation; patients with ST-segment elevation myo-
cardial infarction (STEMI) exhibit a higher incidence
of bleeding and a higher proportion of access
site bleeds than those with non–ST-segment eleva-
tion myocardial infarction (NSTEMI) or unstable
angina (6).
Transradial access (TRA) has been adopted as the
default approach for PCI in many European and North
American centers because of its proven beneﬁcial
effect on access site–related complications and
mortality (6–8). It is widely believed that the mor-
tality beneﬁts seen with TRA are mediated through a
reduction in major bleeding complications (9–11). A
recent subgroup analysis of the RIVAL study found
that TRA signiﬁcantly reduces mortality as well as
the primary composite outcome of mortality, MI,
stroke, and non–CABG-related major bleeding in the
STEMI subgroup; non-CABG major bleeding was not
affected (12). In contrast, TRA was not associated
with any impact on these outcomes in the NSTEMI
cohort (12).
This ﬁnding may be related to the underlying
bleeding risk in these patient groups. For example,
30-day Thrombolysis In Myocardial Infarction (TIMI)
major bleeding increased from 0.7% in patients with
stable angina to 1.6% and 2.6% in the NSTEMI and
STEMI groups, respectively, in a recent patient-
level pooled analysis of the REPLACE-2 (RandomizedEvaluation of PCI Linking Angiomax to
Reduced Clinical Events), ACUITY (Acute
Catheterization and Urgent Intervention
Triage strategY), and HORIZONS-AMI (Har-
monizing Outcomes with Revascularization
and Stents in Acute Myocardial Infarction)
studies (13). Similarly, major bleeding in-
creased from 1.1% in patients with stable
angina to 1.8% and 4.5% in the NSTEMI and
STEMI groups in an analysis of the National
Cardiovascular Data Registry known as Cath-
PCI (14). It is therefore possible that the
greatest beneﬁt of TRA occurs in those pa-
tients at greatest risk from bleeding com-
plications, although previous research has
not systematically studied the inﬂuence of
baseline bleeding risk on access site–related
outcomes.
The present paper is an observational
analysis of TRA versus transfemoral access
(TFA) utilization and their associated outcomes in a
nonselected national cohort derived from the British
Cardiovascular Intervention Society (BCIS) database
over a 6-year period. We aimed to study the impact of
baseline peri-procedural bleeding risk on access
site–related outcomes and whether baseline bleeding
risk inﬂuences access site choice within the United
Kingdom.
METHODS
THE BCIS DATABASE. The BCIS collects data relating
to the United Kingdom’s nationwide practice of PCI
(15). The data are collected via the Central Cardiac
Audit Database under the auspices of the National
Institute for Cardiovascular Outcomes Research. The
aim is to record all PCI procedures performed in any
U.K. hospital. In 2011, w99% of all PCI procedures
performed in U.K. National Health Service (NHS)
hospitals had been entered into the database.
The BCIS database documents clinical, procedural,
and outcomes information with a total of 113 vari-
ables. As of December 2011, there were w459,775
records in the BCIS database, with w80,000 new
records added each year. Mortality tracking is per-
formed by the Medical Research Information Service
by using each patient’s NHS number, which provides
a unique identiﬁer for any person registered with the
NHS in England and Wales.
STUDY DEFINITIONS. The data presented relate to all
reported PCI procedures undertaken in patients in
the United Kingdom between January 1, 2006, and
December 31, 2011. PCI procedures performed via the
left or right femoral artery or the left or right radial
TRA
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respectively. Patients in whom the access site was
unknown were excluded.
In-hospital major bleeding complications were
deﬁned as a composite of reported gastrointestinal
bleed, intracerebral bleed, retroperitoneal hematoma,
blood or platelet transfusion, or an arterial access site
complication requiring surgery (7).
Two primary outcomes were examined. The ﬁrst
was 30-day mortality deﬁned as any-cause death. The
mortality data for each procedure were validated
against Ofﬁce for National Statistics records, the
United Kingdom’s statutory deaths register. The sec-
ond outcome was in-hospital major bleeding compli-
cation as previously deﬁned.
CALCULATION OF BLEEDING RISK SCORE. To pre-
dict non-CABG–related TIMI major bleeding in
patients undergoing PCI in the elective and acute
setting, the Mehran score was developed through a
patient-level pooled analysis of the REPLACE-2,
ACUITY, and HORIZONS-AMI trials (13). The risk
score consists of 7 variables: serum creatinine
level, age, sex, presentation, white blood cell count,
cigarette smoking, and anticoagulant agent use.
In the present analysis, we modiﬁed the risk score
published by Mehran et al. (13) to deﬁne the baseline
risk of bleeding complications in patients who
underwent PCI in the BCIS database. Our modiﬁed
Mehran score, illustrated in Online Table 1, was
calculated for each participant based on age, sex,
clinical presentation, smoking history, renal function,
and antithrombotic medications, with an integer
score assigned for each category. Modiﬁcations
were necessary because measurement of white blood
cell count and actual serum creatinine, both of
which are required to calculate the Mehran score,
are not recorded in the BCIS database. Severe
renal dysfunction was deﬁned as a history of renal
disease and creatinine levels >200 mmol/l or patients
requiring dialysis. Moderate renal dysfunction
was deﬁned as a history of renal disease with creati-
nine levels <200 mmol/l or functioning transplant.
No renal impairment was deﬁned as no history
of renal disease and creatinine levels <200 mmol/l
as per the BCIS deﬁnition. The remaining categories
and integer scores associated with each category
remained unchanged from the original Mehran
score (13).
STATISTICAL ANALYSIS. All statistical calculations
were performed by using Stata version 12.1 (Stata
Corp, College Station, Texas). Data are expressed as
arithmetic mean  SD and number (%) for continuous
and categorical variables, respectively. To compareproportions for nonparametric data, we used the
chi-square test. Tests for linear trend used chi-square
models.
Using the aforementioned template and as illus-
trated in Online Table 1, we calculated individual
modiﬁed risk scores and further stratiﬁed procedures
into 1 of 4 categories of risk bleeding as deﬁned in
Mehran’s original paper: low, moderate, high, and
very high corresponding to integer scores <10, 10 to
14, 15 to 19, and $20.
We estimated odds ratios (ORs) of mortality or
bleeding within 30 days per site of access (TFA vs.
TRA) by using logistic regression models. Multivariate
adjustment included the continuous variables age
and dichotomized categorical variables (yes vs. no):
sex (female vs. male), peripheral vascular disease,
hypertension, hypercholesterolemia, type 2 diabetes,
bivalirudin use, and glycoprotein IIb/IIIa inhibitor
use. The other categorized variables included smok-
ing status (current or ex-smoker vs. never), acute
coronary syndrome type (STEMI or NSTEMI vs.
elective/stable), left ventricular function (poor or
moderate vs. good), and renal impairment (severe or
moderate vs. normal). The 4 categories of risk
bleeding (<10, 10 to 14, 15 to 19, and $20) were also
included (<10 as comparator). Both the Akaike and
Bayesian information criteria were used to assess
model parsimony and goodness-of-ﬁt.
For all models, we tested for interaction by adding
terms for access site and the modiﬁed Mehran risk
category. Tests for statistically signiﬁcant in-
teractions used the Wald test of the terms; if the
interaction terms were not signiﬁcant, they were
excluded from the ﬁnal models.
Model discrimination (i.e., the degree to which the
prognostic score enables the discrimination between
patients with a favorable or unfavorable outcome)
was quantiﬁed by using the C-statistic, interpreted as
the area under the receiver-operating characteristic
curve for a corresponding logistic regression model
(16). Bootstrapping techniques were used to validate
the model (i.e., to adjust the estimated model per-
formance for overoptimism or overﬁtting). We also
adjusted our estimate of the C-statistic for optimism
by using 10-fold cross-validation with random
resampling to generate average predicted probabili-
ties (17).
The Hosmer-Lemeshow goodness-of-ﬁt test (18) for
logistic regression models was used to assess the
validity of the models. The statistic is computed as
the Pearson chi-squared test from a contingency table
of observed and expected frequencies. A signiﬁcant
test result indicates one important kind of invalidity
of a model.
TABLE 1 Baseline Clinical and Procedural Characteristics for
Radial and Femoral Access Sites
Radial
(n ¼ 151,412)
Femoral
(n ¼ 197,277) p Value
Age, yrs 63.8 (63.7–63.9) 64.7 (64.6–64.8) <0.0001
Male 114,946 (75.9%) 143,412 (72.7%) <0.0001
Diabetes 26,308 (17.5%) 36,628 (18.9%) <0.0001
Hypertension 79,736 (54.9%) 104,397 (55.2%) 0.159
Hypercholesterolemia 86,390 (59.5%) 113,762 (60.1%) 0.0004
Previous AMI 38,099 (26.1%) 55,581 (30.8%) <0.0001
Previous CABG 7,060 (4.8%) 20,969 (10.9%) <0.0001
Family history 67,416 (47.3%) 87,218 (48.5%) <0.0001
Smoking status
Current 41,518 (27.4%) 45,084 (22.9%) <0.001
Ex-smoker 57,306 (37.9%) 81,690 (41.4%) <0.001
Never smoked 52,588 (34.7%) 70,503 (35.7%) 0.003
PVD 7804 (5.4%) 9073 (4.8%) <0.0001
Clinical syndrome
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1557To control for potentially confounding factors, we
used propensity score methods with nearest-
neighbor matching to account for the confounding
arising from differences in clinical characteristics of
patients treated with TRA versus TFA. A propensity
score was estimated for each episode of radial or
femoral access given the following variables: age,
sex, diabetes, hypertension, cholesterol, previous
MI, CABG, syndrome of presentation, peripheral
vascular disease, and modiﬁed Mehran score.
Mahalanobis distance matching with the propensity
score as the distance matrix was then undertaken
to generate a 1:1 matched cohort. Standardized
differences between groups were estimated to
assess the balance achieved by matching; a baseline
characteristic was considered well balanced if the
standardized difference was <10%. We then esti-
mated ORs of mortality or bleeding within 30 days
in relation to the site of access (TFA vs. TRA) by
using logistic regression models in the adjusted
dataset.
RESULTS
BASELINE CLINICAL CHARACTERISTICS AND INCIDENCE
OF PERI-PROCEDURAL FACTORS. A total of 348,689 PCI
procedures were performed in patients in the UnitedPCI procedures performed in the UK
(2006-2011)
459,775
Eligible PCI procedures
459,487
Eligible single access site
PCI procedures
434,887
PCI procedures analyzed
348,689
Excluded patients with missing
data for modified Mehran Score
n=86,198
Excluded patients with
multiple access sites used
n=24,600
Excluded patients <20 years
and >105 years old
n=288
FIGURE 1 Flowchart of Eligibility and Exclusion of Patients
The starting cohort comprised 459,775 patients; after exclusions,
348,689 eligible procedures were included in the analysis.
PCI ¼ percutaneous coronary intervention.Kingdom between January 1, 2006, and December 31,
2011, in which access site utilization was known
and in which a modiﬁed Mehran score could be
calculated (Figure 1). In 151,412 patients (43.4%), TRA
was used, and TFA was used in 197,277 patients
(56.6%). Patients undergoing PCI via TFA were older
and more likely to be diabetic (Table 1). Those who
underwent PCI via TRA were more likely to presentACS 93,023 (61.4%) 107,287 (54.4%) <0.0001
Elective 58,389 (38.6%) 89,990 (45.6%) <0.0001
Major bleed 418 (0.3%) 1,836 (0.8%) <0.0001
30-day mortality 1384 (0.9%) 3434 (1.7%) <0.0001
Modiﬁed Mehran score 10.59 (10.56–10.61) 10.67 (10.65–10.70) <0.0001
Modiﬁed Mehran risk score
<10 71,771 (43.21%) 94,312 (56.79%) <0.0001
10–14 47,507 (44.21%) 59,948 (55.79%) <0.0001
15–19 23,479 (43.81%) 30,113 (56.19%) <0.0001
$20 8,655 (48.15%) 12,984 (51.85%) <0.0001
Target vessel*
LAD 68,219 (46.1%) 85,088 (44.2%) <0.001
RCA 45,293 (30.6%) 57,570 (29.9%) <0.001
LCx 27,522 (18.6%) 34,402 (17.9%) 0.024
LMS 2,995 (2.0%) 5,049 (2.6%) <0.001
Grafts 3,925 (2.6%) 10,288 (5.3%) <0.001
GP IIb/IIIa† 42,203 (27.9%) 47,643 (24.2%) chi-square ¼ 449.99;
<0.0001
Bivalirudin use‡ 3,196 (2.1%) 3,090 (1.6 %) chi-square ¼ 143.45;
<0.0001
Cardiogenic shock 1,314 (0.9%) 3,755 (2.1%) chi-square ¼ 712.24;
<0.0001
IABP use 817 (0.2%) 3,094 (0.6%) chi-square ¼ 851.67;
<0.0001
DES use 66,038 (46.5%) 70,551 (40.9%) chi-square ¼ 993.38;
<0.0001
No. of stents used 1.50 (1.49–1.51) 1.50 (1.49–1.50) F ¼ 3.70; <0.05
Values are mean (range) or n (%). *Two-sample test of proportions. †Glycoprotein (GP) IIb/IIIa use versus
heparin. ‡Bivalirudin versus heparin–GP2b/3a.
ACS ¼ acute coronary syndrome(s); AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass graft;
DES ¼ drug-eluting stent(s); IABP ¼ intra-aortic balloon pump; LAD ¼ left anterior descending; LCx ¼ left
circumﬂex; LMS ¼ left main stem; PVD ¼ peripheral vascular disease; RCA ¼ right coronary artery.
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FIGURE 2 Crude Bleeding Rates According to
Bleeding Risk Category
Histogram of the crude in-hospital bleeding rates (%) according
to modiﬁed Mehran risk score categories.
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1558with an acute coronary syndrome. Table 1 also details
procedural characteristics. A greater proportion of PCI
procedures via TFA were performed in patients with
cardiogenic shock or requiring an intra-aortic balloon
pump. Glycoprotein IIb/IIIa and drug-eluting stent
usage was more common in procedures via TRA.Multivariable Logistic Regression of Risk of In-Hospital Major
30-Day Mortality
In-Hospital Major Bleed* 30-Day Mortality†
e (radial) 0.26 (0.22–0.31)‡ 0.82 (0.73–0.91)‡
or use (yes) 2.10 (1.82–2.44)‡ 1.29 (1.15–1.44)‡
n
1.00
tion fair 0.95 (0.80–1.12) 2.69 (2.37–3.05)‡
tion poor 1.06 (0.82–1.38) 6.81 (5.90–7.85)‡
yes) 1.05 (0.88–1.25) 1.37 (1.21–1.54)‡
esterolemia (yes) 1.19 (1.02–1.40)§ 1.14 (1.01–1.28)§
ion (yes) 1.01 (0.87–1.18) 0.90 (0.81–1.01)
1.21 (0.94–1.57) 1.53 (1.30–1.80)‡
ic shock (yes) 1.14 (0.80–1.61) 7.25 (6.13–8.58)‡
yes) 3.90 (2.88–5.29)‡ 2.67 (2.22–3.21)‡
ABG 1.05 (0.82–1.33) 0.90 (0.75–1.08)
ehran risk score
1.00
1.54 (1.27–1.86)‡ 2.23 (1.89–2.63)‡
2.77 (2.28–3.37)‡ 4.76 (4.05–5.59)‡
4.06 (3.25–5.08)‡ 7.86 (6.61–9.33)‡
dds ratio (95% CI). *For in-hospital major bleed model, the naive estimate of the C-
the model was 0.77 (0.75–0.78), and the adjusted C-statistic was 0.76 (0.75–0.78)
rapping. †For 30-day mortality model, the adjusted C-statistic was 0.86 (0.75–0.87)
trapping. ‡p < 0.0001. §p < 0.05. Age, sex, renal function, bivalirudin use, acute
ndrome type, and smoking were not included separately because they were used to
odiﬁed Mehran risk score.
ventricular; other abbreviations as in Table 1.ASSOCIATION OF MODIFIED MEHRAN BLEEDING RISK
SCORE AND IN-HOSPITAL MAJOR BLEEDING. Baseline
bleeding risk was determined for each of the
348,689 participants by calculating individual modi-
ﬁed Mehran scores, and its relationship with
in-hospital major bleeding events was studied.
Figure 2 illustrates the relationship between crude
major in-hospital bleeding rates in all 348,689 pro-
cedures and modiﬁed Mehran bleeding risk score
category (13); low, moderate, high, and very high
bleeding risk corresponded to integer scores <10, 10
to 14, 15 to 19, and $20, respectively. Thus, as the
modiﬁed Mehran score increased, the risk of a sig-
niﬁcant bleed rose substantially, with each unit in-
crease in the modiﬁed Mehran score associated with
a 10% additional risk of in-hospital major bleed
(OR: 1.10 [95% conﬁdence interval (CI): 1.09 to 1.11];
p < 0.0001). Multivariate logistic regressions were
performed to identify independent predictors of in-
hospital major bleeding complications in the pa-
tients who underwent PCI. The naive estimate of the
C-statistic for the model was 0.77 (0.75 to 0.78), and
the adjusted C-statistic was 0.76 (0.75 to 0.78) after
bootstrapping. We found no interaction between
access site and the Mehran score when the interaction
terms were included in the model. Among the stron-
gest independent predictors of in-hospital major
bleeding complications was baseline bleeding risk as
assessed by using the Mehran score (Table 2).
IMPACT OF BLEEDING RISK ON ALL-CAUSE
MORTALITY. The impact of baseline bleeding risk on
30-day mortality outcomes was subsequently stud-
ied. Figure 3 illustrates the crude 30-day mortality in
all 348,689 patients and its relationship with baseline
bleeding risk as calculated by using the modiﬁed
Mehran risk score. As before, increasing baseline
bleeding risk (assessed according to the modiﬁed
Mehran score) was associated with increased risk of
30-day mortality. Each unit increase in baseline
bleeding risk (assessed according to the modiﬁed
Mehran score) was associated with increased risk of
30-day mortality (univariate OR: 1.18 [95% CI: 1.17 to
1.18]; p < 0.0001); the adjusted C-statistic was 0.76
(0.76 to 0.77) after bootstrapping.
Multivariate logistic regression was performed to
identify independent predictors of 30-day mortality
in the patients undergoing PCI. The strongest inde-
pendent predictor of 30-day mortality was bleeding
risk at baseline (Table 2). For example, patients at
very high bleeding risk (modiﬁed Mehran score $20)
had an associated OR of 7.86 (95% CI: 6.61 to 9.33; p <
0.0001) for 30-day mortality; even those at moderate
risk of bleeding complications (modiﬁed Mehran
score 10 to 14) had an associated OR of 2.23 (95% CI:
86
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FIGURE 3 Crude Mortality Rates According to
Bleeding Risk Category
A histogram of the crude 30-day mortality rates (%) according to
modiﬁed Mehran risk score categories.
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15591.89 to 2.63; p < 0.0001). Other independent pre-
dictors of 30-day mortality included diabetes (OR:
1.37 [95% CI: 1.21 to 1.54]; p < 0.0001) and TRA (OR:
0.82 [95% CI: 0.73 to 0.91]; p < 0.0001). The adjustedTABLE 3 Distribution of Demographic and Clinical Variables Accordin
Modiﬁ
Low (<10) Moderate (10–1
Age, yrs 59.6 (59.5–59.6) 65.0 (64.9–6
Male 167,119 (95.0) 73,172 (64.6)
Diabetes 32,352 (18.6) 19,348 (17.3)
Hypertension 89,886 (53.3) 58,564 (54.0)
Hypercholesterolemia 106,056 (62.9) 63,458 (58.5)
Previous AMI 51,723 (31.3) 27,973 (26.4)
Previous CABG 16,307 (9.5) 8,371 (7.6)
Previous CVA 4,805 (2.9) 4,619 (4.3)
Family history 85,978 (52.6) 49,377 (47.3)
Smoking status
Current 67,818 (38.5) 35,423 (31.3)
Ex-smoker 88,133 (50.1) 34,978 (30.9)
Never smoked 20,045 (11.4) 42, 948 (37.9)
PVD 6,420 (3.8) 5,554 (5.1)
Q-wave on ECG 16,914 (12.5) 12,949 (14.9)
ACS
Stable 110,076 (62.5) 38,765 (34.2)
NSTEMI 54,127 (30.8) 49,774 (43.9)
STEMI 11,793 (6.7) 24,810 (21.9)
Bivalirudin 4,482 (2.6) 1,417 (1.3)
Any circulatory support 1,213 (0.7) 1,890 (1.0)
Shock 947 (0.58) 1,630 (1.5)
Ventilated 863 (0.6) 986 (1.0)
GP inhibitor use 34,258 (21.0) 32,596 (30.8)
Radial access site 71,771 (43.2) 47,507 (44.2)
Values are mean (range) or n (%). *Derived from chi-square/analysis of variance tests.
CVA ¼ cardiovascular accident; ECG ¼ electrocardiogram; NSTEMI ¼ non–ST-segm
other abbreviations as in Table 1.C-statistic for this model was 0.86 (0.85 to 0.88) after
bootstrapping. No interaction was found between
access site and Mehran score when the interaction
terms were included in this model.
RELATIONSHIP BETWEEN BLEEDING RISK AND
ACCESS SITE CHOICE. We subsequently investi-
gated whether baseline bleeding risk was associated
with access site choice. The baseline clinical and
procedural demographic characteristics in the 4
groups stratiﬁed according to baseline bleeding risk
are presented in Table 3. At the lowest risk of bleeding
complications (modiﬁed Mehran score <10), TRA was
used in 71,771 (43.2%) of 166,083 PCI procedures;
among the 21,599 patients at highest risk of bleeding
complications (modiﬁed Mehran score $20), TRA was
used in 8,655 (40.1%) of 21,559 patients, paradoxically
illustrating that TRA was used signiﬁcantly less as an
access site in those at highest risk from bleeding
complications (p < 0.0001).
RELATIONSHIP BETWEEN BLEEDING RISK AND ACCESS
SITE CHOICE ON MORTALITY AND BLEEDING OUT-
COMES. Mortality outcomes were studied according
to access site utilization. The 30-day mortality ing to Bleeding Risk Deﬁned by Using the Modiﬁed Mehran Score
ed Mehran Score
p Value*4) High (15–19) Very High ($20)
5.0) 72.2 (72.1–72.3) 77.9 (77.8–78.0) <0.0001
28,321 (50.1) 4,126 (18.0) <0.0001
9,850 (17.7) 4,735 (21.0) <0.0001
30,972 (57.0) 14,137 (64.1) <0.0001
29,651 (54.5) 11,954 (54.2) <0.0001
14,019 (26.5) 6,152 (28.8) <0.0001
3,463 (6.3) 1,394 (6.3) <0.0001
3,286 (6.0) 1,760 (8.0) <0.0001
20,142 (39.3) 6,773 (33.3) <0.0001
18,067 (31.9) 9,550 (41.7)
17,176 (30.4) 6,459 (28.2) <0.0001
21,339 (37.7) 6,881 (30.1)
3,780 (7.0) 2,132 (9.7) <0.0001
8,038 (18.3) 3658 (20.4) <0.0001
7,600 (13.4) 1,602 (7.0)
26,988 (47.7) 10,875 (47.5) <0.0001
21,994 (38.9) 10,413 (45.5)
528 (0.9) 70 (0.3)
1,992 (3.8) 1,150 (5.4) <0.0001
1,823 (3.3) 1,130 (5.1) <0.0001
741 (1.5) 333 (1.7) <0.0001
19,680 (37.1) 7,629 (35.5) <0.0001
23,479 (43.2) 8,655 (40.1) <0.0001
ent elevation myocardial infarction; STEMI ¼ ST-elevation myocardial infarction;
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and 3,434 (1.74%) of 197,277 in the TFA cohort.
After adjustment of baseline covariates, multivariate
logistic regression analysis revealed that TRA was
independently associated with a reduction in 30-
day mortality (OR: 0.65 [95% CI: 0.59 to 0.72];
p < 0.0001).
The impact of baseline bleeding risk on 30-day
mortality according to access site was also studied.
Figure 4A illustrates the actual 30-day mortality rates
in the TRA and TFA cohorts. As before, as the baseline
risk of bleeding (calculated with the modiﬁed Mehran
score) rises, both cohorts experienced an increase in
30-day mortality. However, there was a clear sepa-
ration in 30-day mortality for the TRA and TFA co-
horts as baseline bleeding risk increased; the absolute10
8
6
4
2
0
Cr
ud
e 
M
or
ta
lit
y 
(%
)
<10 ≥2010-14 15-19
Bleeding Risk Category
3
2
1
0
<10 ≥2010-14 15-19
Bleeding Risk Category
Cr
ud
e 
Bl
ee
di
ng
 R
at
es
 (%
)
Radial Femoral
A
B
FIGURE 4 Crude Mortality and Bleeding Rates for
Radial Versus Femoral Cohorts According to
Bleeding Risk Category
(A) A histogram of the crude 30-day mortality rates (%) ac-
cording to modiﬁed Mehran risk score categories in the femoral
and radial cohorts. (B) A histogram of the crude in-hospital
bleeding rates (%) according to modiﬁed Mehran risk score
categories in the femoral and radial cohorts.difference in 30-day mortality was thus greatest at
the highest baseline bleeding risk (as deﬁned by using
the modiﬁed Mehran score). A similar relationship
was observed for major bleeding events (Figure 4B).
Figure 5 illustrates the ORs for 30-day mortality for
TRA versus TFA access according to the 4 modiﬁed
Mehran categories of bleeding risk. The mortality
beneﬁt associated with TRA increased as the bleeding
risk (deﬁned according to the modiﬁed Mehran score)
increased. For example, in the lowest bleeding risk
category (modiﬁed Mehran score <10), TRA was
associated with a 27% reduction in 30-day mortality
(OR: 0.73 [95% CI: 0.62 to 0.86]); in the highest
bleeding risk category (modiﬁed Mehran score $20),
TRA was associated with a 47% reduction in 30-day
mortality (OR: 0.53 [95% CI: 0.47 to 0.61]), suggest-
ing that the greatest beneﬁt of TRA was recorded in
those at highest risk of bleeding complications.
PROPENSITY SCORE ANALYSES. To account for
confounding variables and bias in our study cohort,
propensity score matching was performed to adjust
for differences in clinical baseline variables (age,
sex, diabetes, hypertension, hypercholesterolemia,
peripheral vascular disease, previous PCI, syndrome
of presentation, previous CABG, and the modiﬁed
Mehran risk score and their interaction terms),
producing a total of 102,664 matched sets (radial
vs. femoral access). The baseline demographic char-
acteristics of the propensity-matched cohorts strati-
ﬁed according to access site (Online Table 2) and0.9
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FIGURE 5 Impact of Radial Access Site on the Univariate ORs
for 30-Day Mortality Outcomes Stratiﬁed According to
Bleeding Score (TFA as Comparator)
The inﬂuence of access site (odds ratio [OR] and 95% conﬁdence
intervals [CIs]) for 30-day mortality outcomes stratiﬁed
according to bleeding score (transfemoral access [TFA] as
comparator). TRA ¼ transradial access.
TABLE 4 Impact of Radial Access Site on the ORs for 30-Day Mortality
Outcomes Stratiﬁed According to Mehran Bleeding Score (TFA as Comparator)
in a Propensity Score–Matched Cohort
Femoral Radial OR 95% CI z Score p Value
<10 232/52,693 142/52,693 0.69 0.56–0.85 –3.46 0.001
10–14 392/32,560 230/32,560 0.67 0.57–0.79 –4.82 <0.0001
15–19 520/13,677 227/13,677 0.49 0.42–0.57 –8.91 <0.0001
$20 232/3,734 94/3,734 0.46 0.36–0.59 –6.25 <0.0001
Femoral and Radial columns are number of patients/number in the propensity-matched cohort.
The adjusted C-statistics after bootstrapping were 0.63 (0.60 to 0.66) for the modiﬁed Mehran
score (MMS) of <10; 0.64 (0.62 to 0.66) for MMS 10 to 14; 0.63 (0.60 to 0.67) for MMS 15 to 19;
and 0.63 (0.60 to 0.64) for MMS $20.
CI ¼ conﬁdence interval; ORs ¼ odds ratios; TFA ¼ transfemoral access.
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of <10, 10 to 14, 15 to 19, and $20 (Online Tables 3 to 6)
are presented.
The crude rates for mortality increased in both the
TRA and TFA cohorts as risk of bleeding calculated
with modiﬁed Mehran score increased. The absolute
difference in 30-day mortality rose as the baseline
bleeding risk (deﬁned by using the modiﬁed Mehran
score) increased. For example, 30-day mortality at
lowest bleeding risk (Mehran score <10) was 0.46%
and 0.32% (p ¼ 0.0005), 1.27% and 0.85% (p < 0.0001)
for a risk score of 10 to 14, and 4.01% and 2.00%
(p < 0.001) with a risk of 15 to 19 for the TFA
and TRA propensity-matched groups, respectively.
In the highest baseline bleeding risk group (Mehran
score $20), 30-day mortality was 6.53% and 3.10%
in the TFA and TRA groups, respectively (p < 0.0001).
The ORs for 30-day mortality are presented in
Table 4, which shows that the mortality beneﬁt
associated with TRA increased as the bleeding risk
(deﬁned according to the modiﬁed Mehran score)
increased.
DISCUSSION
In our current analysis of nearly 350,000 PCI pro-
cedures performed in the United Kingdom, we found
that use of TRA was independently associated with a
reduction in 30-day mortality outcomes and that the
magnitude of this mortality effect was related to
baseline bleeding risk, with those at highest risk of
bleeding complications gaining the greatest beneﬁt
from adoption of TRA for PCI. Furthermore, our
analysis suggests that in a national setting, access site
choice does not seem to be inﬂuenced by baseline
bleeding risk and, paradoxically, that TRA utilization
rates are lower in those patients at highest risk of
bleeding complications.
Peri-procedural major bleeding complications are
among the most powerful independent predictors of
mortality (1–3,13,19,20), with a greater impact on
mortality than peri-procedural MI (13,20). Our data
also suggest that baseline bleeding risk is one of the
strongest predictors of 30-day mortality for those
patients at highest baseline risk from bleeding com-
plications (modiﬁed Mehran score $20); they had an
8-fold greater risk of 30-day mortality than those at
lowest risk from bleeding complications (modiﬁed
Mehran score <10).
Several studies have suggested that at least
one-third of such bleeding complications are related
to access site (4,5), with TFA a major determinant of
adverse outcomes in those patients who sustain
bleeding complications during PCI (21). Adoption ofTRA has been shown to be associated with lower
mortality (6–8) through a reduction in major bleeding
complications in various studies (9–11).
Data derived from previous studies suggest that
the greatest beneﬁt of TRA in reducing mortality
outcomes may be achieved in those at greatest risk of
bleeding complications. A recent subgroup analysis of
the RIVAL study found that TRA reduced mortality as
well as the primary composite outcome in the STEMI
subgroup but was not associated with any impact on
these outcomes among the NSTEMI subgroup (12).
This ﬁnding may have been related to the higher
baseline bleeding risk of the STEMI versus NSTEMI
cohort. For example, in RIVAL, non-CABG–related
major bleeding occurred in 0.87% of the STEMI cohort
and 0.57% of the NSTEMI group, whereas major
bleeding in the ACUITY study occurred in 3.1% of the
STEMI group and 2.26% of the NSTEMI group.
To our knowledge, our analysis is the ﬁrst to
investigate the inﬂuence of baseline bleeding risk on
access site–related outcomes. We found a separation
in mortality risk between TRA and TFA increasing as
baseline bleeding risk increased, with the maximal
beneﬁcial effect of TRA observed in those patients
with the greatest baseline bleeding risk. However, no
association between baseline bleeding risk and access
site choice was observed.
Various possible explanations may account for our
observations. First, many of the bleeding risk strati-
ﬁcation scores have been published recently and
therefore could not have been used before 2010.
Second, many of these risk scores require blood
results such as serum creatinine (13,20,22), white
blood cell count (13,20), baseline hemoglobin (20), or
hematocrit (22), which may not be available on pre-
sentation in many patients at the highest risk of
bleeding complications (e.g., those undergoing pri-
mary PCI or patients with cardiogenic shock or un-
stable NSTEMI); this limitation makes assessment of
CENTRAL ILLUSTRATION Multivariate Predictors (Odds Ratios) of
Peri-Procedural In-Hospital Major Bleeding Complications After PCI
Multivariate logistic regression analysis for the risk of in-hospital major bleeding
complications used a model that included such covariates as access site, clinical syn-
drome, age, sex, hypertension, peripheral vascular disease (PVD), smoking history,
renal failure, previous acute myocardial infarction, previous coronary artery bypass
graft surgery, diabetes, intra-aortic balloon pump (IABP) use, cardiogenic shock, and
glycoprotein (GP) IIb/IIIa use. NSTEMI ¼ non–ST-segment elevation myocardial infarc-
tion; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation
myocardial infarction; UA ¼ unstable angina.
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scores difﬁcult.
Third, procedural-related factors might also
affect access site choice in patients at highest risk
of bleeding complications. Both female sex and
increasing age raise bleeding risk (13,20,22,23), but
they also make TRA more technically challenging.
Finally, most of the risk stratiﬁcation scores have an
integer score assigned to patients presenting with
STEMI (13,20,23) who are at highest risk of bleeding
complications. Given that such patients may be un-
stable at presentation, operators (particularly at the
start of their learning curve) might ﬁnd TRA chal-
lenging and therefore opt for TFA instead.
STUDY STRENGTHS. The BCIS dataset includes an
almost complete collection of all PCI procedures per-
formed in the United Kingdom. In addition to incor-
porating all-comers, this dataset reﬂects a national,
real-world experience that includes many high-risk
patients encountered daily who are often excluded
from randomized controlled trials. Furthermore, the
present analysis included close to 350,000 PCI pro-
cedures, representing one of the largest analyses ofaccess site–related outcomes in PCI and the ﬁrst to
systematically study the relationship between those
outcomes and baseline bleeding risk.
STUDY LIMITATIONS. First, only 80% of the cohort
contained in the BCIS dataset (through December 31,
2011) was included in this analysis; the remaining
20% had data missing for $1 parameter necessary to
calculate our modiﬁed Mehran score. Second, we
modiﬁed the risk scores published by Mehran to
deﬁne the baseline risk of bleeding complications in
BCIS database patients who underwent PCI. Modiﬁ-
cations were necessary because actual serum creati-
nine or white blood cell count information included
in the Mehran score is not entered into the BCIS
database, although other score components remained
unchanged. Although our predicted rates of bleeding
for a given Mehran score are lower than the original
Mehran score report (13), this ﬁnding may be related
to both differences in the deﬁnition of major bleed-
ing used in the current analysis as well as the omis-
sion of white blood cell count from our modiﬁed
score. Nevertheless, our modiﬁed Mehran score
demonstrated a strong relationship between increas-
ing integer score and the escalating risk of major
in-hospital bleeding complications, with each unit
increase in the modiﬁed Mehran score associated
with a 10% increased risk of in-hospital major
bleeding. The modiﬁed Mehran risk score was the
strongest predictor of in-hospital major bleeding
complications on multivariate analysis.
Third, although mortality tracking within the
United Kingdom is very robust, cause of death is not
currently available, and all other outcomes and
complications such as bleeding complications are
self-reported and not formally validated by BCIS,
potentially resulting in underreporting. Finally,
bleeding deﬁnitions used in the BCIS dataset are
different from those frequently used in clinical trials,
such as ACUITY and TIMI; thus, we could not assess
the performance of our modiﬁed Mehran score by
using these bleeding deﬁnitions.
CONCLUSIONS
Use of TRA was independently associated with a
reduction in 30-day mortality, and the magnitude of
this mortality effect was related to baseline bleeding
risk: those at highest risk of bleeding complications
gained the greatest beneﬁt from TRA adoption for
PCI. Our analysis suggests that in a national setting,
access site choice does not currently seem to be
inﬂuenced by baseline bleeding risk and that use
of TRA was lowest in those patients at highest risk of
bleeding complications.
PERSPECTIVES
COMPETENCY IN PATIENT CARE: The patient’s risk of
bleeding should be carefully considered in selecting the optimal
approach to vascular access in patients undergoing percutaneous
coronary intervention.
COMPETENCY IN MEDICAL KNOWLEDGE: Patients at
highest risk of bleeding complications gain the greatest beneﬁt
from use of radial artery access for percutaneous coronary
intervention.
TRANSLATIONAL OUTLOOK: Validation of risk assess-
ment schemes that encompass a broad array of clinical
outcomes, including the success of revascularization as
well as bleeding and other complications to guide optimal
selection of vascular access sites, could strengthen the
evidence base and accelerate their incorporation into
practice guidelines.
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bleeding risk as part of the decision-making pro-
cess for optimal access site choice before PCI,
in keeping with the current American College of
Cardiology Foundation/American Heart Association/
Society for Cardiovascular Angiography and Inter-
ventions guidelines for PCI in which evaluation of
bleeding risk before PCI was given a class I recom-
mendation (24). Combining TRA with optimal phar-
macological strategies has great potential to reduce
both access site and systemic bleeding, resulting in
better patient outcomes after PCI, particularly in the
groups of patients at highest risk of bleeding com-
plications, such as those presented in the Central
Illustration.
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